Holen Sie sich die Stockscreener-App
1.49
0.00%
0.00
Handel nachbörslich:
1.47
-0.02
-1.34%
Schlusskurs vom Vortag:
$1.49
Offen:
$1.5
24-Stunden-Volumen:
365.35K
Relative Volume:
1.09
Marktkapitalisierung:
$97.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.04M
KGV:
-0.8817
EPS:
-1.69
Netto-Cashflow:
$-27.38M
1W Leistung:
-7.45%
1M Leistung:
-5.70%
6M Leistung:
-43.77%
1J Leistung:
+7.19%
1-Tages-Spanne:
$1.46
$1.515
1-Wochen-Bereich:
$1.46
$1.68
52-Wochen-Spanne:
$1.08
$3.79
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Firmenname
Regulus Therapeutics Inc
Sektor
Branche
Telefon
858-202-6300
Adresse
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-02 | Eingeleitet | Oppenheimer | Outperform |
| 2024-03-18 | Eingeleitet | Leerink Partners | Outperform |
| 2018-03-28 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Eingeleitet | Leerink Partners | Outperform |
| 2017-06-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-03-06 | Bestätigt | Wedbush | Outperform |
| 2017-01-30 | Herabstufung | Needham | Buy → Hold |
| 2017-01-30 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-11-02 | Bestätigt | Needham | Buy |
| 2016-07-25 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | FBR Capital | Outperform |
| 2016-06-28 | Bestätigt | Needham | Buy |
| 2016-06-07 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-04-13 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2015-04-21 | Fortgesetzt | FBR Capital | Outperform |
| 2014-11-24 | Eingeleitet | Deutsche Bank | Buy |
| 2014-08-07 | Bestätigt | FBR Capital | Outperform |
| 2013-08-14 | Bestätigt | Needham | Buy |
Alle ansehen
Regulus Therapeutics Inc Aktie (RGLS) Neueste Nachrichten
Vanguard Group Inc's Strategic Acquisition in Regulus Therapeuti - GuruFocus.com
HC Wainwright Reiterates Buy Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives $10.80 Average PT from Analysts - MarketBeat
Regulus Therapeutics secures exclusive license for kidney disease treatment - Investing.com India
Regulus Therapeutics secures exclusive license for kidney disease treatment By Investing.com - Investing.com South Africa
Regulus Therapeutics Inc. Enters into Patent & Technology License Agreement with the Board of Regents of the University of Texas System - Marketscreener.com
Financial Survey: Regulus Therapeutics (NASDAQ:RGLS) & Ironwood Pharmaceuticals (NASDAQ:IRWD) - Defense World
Renaissance Technologies LLC Has $211,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
HC Wainwright Reaffirms "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
RGLSRegulus Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PR Newswire
Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $10.80 - MarketBeat
Company’s Banking Stock: Dissecting a -7.22% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Regulus Therapeutics Inc [RGLS] stock for 7,280 USD was acquired by Collier Kathryn J - Knox Daily
Regulus Therapeutics Inc. (NASDAQ:RGLS) Shares Sold by CVI Holdings LLC - MarketBeat
Companies Like Regulus Therapeutics (NASDAQ:RGLS) Are In A Position To Invest In Growth - Simply Wall St
ProMIS Neurosciences (NASDAQ:PMN) versus Regulus Therapeutics (NASDAQ:RGLS) Critical Contrast - Defense World
Investing in Regulus Therapeutics Inc (RGLS) Is Getting More Attractive - Knox Daily
Victory Capital Management Inc. Has $645,000 Position in Regulus Therapeutics Inc. (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Stock Rating Upgraded by StockNews.com - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Upgraded to "Sell" by StockNews.com - MarketBeat
Oppenheimer’s latest rating for RGLS stock - Knox Daily
RGLS stock rated an Outperform by Oppenheimer - Knox Daily
Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Regulus Therapeutics (NASDAQ:RGLS) Raised to Sell at StockNews.com - MarketBeat
Regulus Therapeutics Inc [RGLS] Director makes an insider purchase of 4,000 shares worth 7280.0. - Knox Daily
Regulus Therapeutics Inc (RGLS) rating initates by Oppenheimer - Knox Daily
How does Regulus Therapeutics Inc (RGLS) change from a tortoise to a hare? - SETE News
Regulus Therapeutics Inc (RGLS) stock analysis: A comprehensive overview - US Post News
Regulus Therapeutics Inc (RGLS)’s stock chart: A technical perspective - US Post News
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - StockTitan
The Attractiveness of Investing In Regulus Therapeutics Inc (RGLS) is Growing - Knox Daily
Market Recap: Regulus Therapeutics Inc (RGLS)’s Positive Momentum, Closing at 1.59 - The Dwinnex
A Guide To The Risks Of Investing In Regulus Therapeutics Inc (RGLS) - Knox Daily
Vanguard Group Inc. Has $2.13 Million Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Longview News-Journal
Oppenheimer Reiterates “Outperform” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Oppenheimer Reiterates Outperform Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Analyzing Regulus Therapeutics Inc (RGLS) After Recent Trading Activity - Knox Daily
Regulus Therapeutics Inc. Forecasted to Earn Q2 2025 Earnings of ($0.20) Per Share (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Earns Buy Rating from HC Wainwright - Defense World
Regulus Therapeutics Inc. Forecasted to Post Q2 2025 Earnings of ($0.20) Per Share (NASDAQ:RGLS) - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Regulus: Q2 Earnings Snapshot - San Antonio Express-News
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - Nasdaq
Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at Oppenheimer - Defense World
RGLS stock rated an Outperform by Leerink Partners - Knox Daily
Finanzdaten der Regulus Therapeutics Inc-Aktie (RGLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regulus Therapeutics Inc-Aktie (RGLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| CALSADA CRISPINA | Chief Financial Officer |
Jan 18 '24 |
Sale |
1.19 |
5,468 |
6,510 |
5,782 |
| Aker Christopher Ray | Sr. VP & General Counsel |
Jan 18 '24 |
Sale |
1.19 |
5,468 |
6,510 |
10,056 |
| Hagan Joseph P | Chief Executive Officer |
Jan 18 '24 |
Sale |
1.19 |
14,580 |
17,359 |
57,112 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):